The Cannabis Consortium Review of the Literature
The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:
- A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.
- There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.
- The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.
What is medical marijuana?
Medical marijuana, also often called medical cannabis, refers to the use of marijuana obtained from an approved source and recommended by a healthcare provider to treat a medical condition. Medical marijuana is composed of the dried leaves, flowers, stems and seeds from the Cannabis genus plants, usually made from strains of Cannabis sativa or Cannabis Indica. The plants of Cannabis genus contain a large number of chemical compounds called phytocannabinoids, of which delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most abundant.
THC is the psychoactive component (the “high”) of the cannabis plant. CBD does not have psychoactive properties, but can have actions on the brain1–3. There are additionally over 100 phytocannabinoids and many other largely uncharacterized compounds in cannabis with the exact composition varying, depending on growing conditions, plant variety, and method of manufacturing/formulation4–8. In keeping with the regulations of a given state or country, medical marijuana can be consumed via inhalation, orally (alone or incorporated into edible food items), topically for designated medical conditions and in suppository form. Medical marijuana products are currently distributed by dispensaries in the U.S and, in some countries, by pharmacies. Regulation of medical marijuana is not uniform and depending on the state’s or country’s governmental regulations, medical marijuana and related products may contain contaminants13.
What are cannabis-based medicines?
Cannabis-based medicines are different from medical marijuana in that these medicines follow strict drug manufacturing regulations established by the US Food and Drug Administration (FDA) or equivalent regulatory bodies abroad. Cannabis-based medicines target the same pathways in the body as cannabis itself and include synthetic analogs of THC and CBD, standardized extracts of marijuana, or novel drugs that target the same pathways in the body as medical marijuana. These drugs have undergone regulated efficacy, toxicity and safety studies although not necessarily for Tourette Syndrome specifically. Once approved, these medications can be prescribed and monitored by a physician.
To date, the FDA has approved one cannabis-based medicine (for Epilepsy) but there are two cannabis-based medicines currently in development specifically for Tourette Syndrome: Therapix Biosciences has completed a Phase II clinical trial and is currently recruiting for Phase III. Abide Therapeutics (recently acquired by Lundbeck) has completed a Phase I trial. Early results from these studies are promising in terms of reduction in tics and/or premonitory urges, but more research is needed.
At the end of this report, we provide a table listing cannabis-based medicines, their approved indications, and their current status of clinical development.
Medical marijuana laws and regulation
At the present time medical marijuana is legal in 33 states and Washington D.C. and is specifically approved for the treatment of Tourette Syndrome in Arkansas, Illinois, Minnesota, Missouri, New Jersey and Ohio. CBD from hemp is now legal federally and readily available nationwide. Across states there is not necessarily uniformity in the testing and verification of medical marijuana and there is no set standard of efficacy in order for a state to approve medical marijuana for a specific medical condition. This variability in regulation complicates both research and treatment of Tourette Syndrome. First, marijuana and cannabis-derived natural products are not federally sanctioned despite being legal in the majority of the United States. In addition, marijuana in all of its forms continues to be classified by the federal government as a Schedule I drug*.
Academic/research institutions are subject to federal regulation and may be unable to approve research efforts on substances that may be legal locally but not federally. The layers of bureaucracy surrounding research of medical marijuana are a major challenge. The TAA supports a drug schedule re-evaluation for marijuana, thus removing regulatory barriers and allowing research to move forward more efficiently.
*Schedule I drugs are thought to have a high potential for abuse, have no currently accepted medical use in treatment, and have a lack of accepted safety. This is inconsistent with the authorization of marijuana use in 33 states and the District of Columbia for stated medical purposes, which the federal government has not interfered with. In addition, on September 27, 2018 the FDA granted the epilepsy medication Cannabidiol (Epidiolex®) classification in the less restrictive schedule V category, making this cannabis-derived drug for treatment resistant epilepsy an exception to the current standard.
The risks and benefits of marijuana for treating Tourette Syndrome
To date there have only been three FDA approved drugs for the treatment of Tourette Syndrome, but due to the potential side effects of these medications, they are not the first line of treatment for the symptoms of TS or Tic Disorders. More often, other better-tolerated medications that are FDA approved, albeit not for Tourette Syndrome, are used “off label”. The TAA recently conducted an impact survey, which found that 47% of adults and 44% of the parents of children with Tourette Syndrome do not feel that their symptoms are adequately controlled by existing medications45. It is in the best interest of the Tourette Syndrome community to explore the efficacy, potential benefits, and risks of any potential therapy, including medical marijuana.
There is a system within our bodies that responds to THC and other chemicals in cannabis called the “endocannabinoid system”14–16. This system modulates the release of most neurotransmitters in the brain including dopamine, glutamate, GABA, opioid peptides, and acetylcholine. When medical cannabis is used its chemicals modulate different receptor systems in the brain and these in turn affect neurotransmitter release. These chemicals also modulate the endocannabinoid system itself. In the basal ganglia region of the brain, a region important in Tourette, the chemicals in medical marijuana can interact with dopaminergic transmission, potentially controlling tics. Modulation of the dopaminergic system in other brain areas and of other transmitter systems might result in improving co-occurring disorders such as ADHD, OCD, and anxiety.
Recent small studies and patient reports suggest medical marijuana and cannabis-derived therapies have been helpful to individuals with Tourette Syndrome and Tic Disorders, but rigorous research studies with large patient numbers are lacking. Anecdotal case reports have long suggested that smoking marijuana or taking THC-containing products in various forms may improve tic symptoms18–27. These reports describe reductions of tics and pre-monitory urges, improvements in sleep, concentration and relaxation, and a reduction in depression, ADHD, OCD, and rage attacks. Standardized interviews of 64 consecutive TS patients seeking treatment in Germany reported that 82% of 17 TS patients who were marijuana users experienced a reduction or complete remission of tic symptoms28. A retrospective review of 19 adult Canadian patients who had used marijuana long-term in various forms (smoked, vaporized and/or edibles) and from various suppliers reported a 60% decrease in tic severity and improvement in co-occurring symptoms, though close to 60% reported adverse effects including sleepiness, dry mouth and appetite and decreased short term memory and concentration29. Since, the reported benefits are subjective descriptions from adults and teens, it is unclear to what extent these benefits are due to the psychoactive effects of marijuana such as reducing anxiety versus a direct impact on tics, or an impact on co-occurring conditions such as ADHD or OCD. It is also unclear whether these effects apply to a majority of TS patients. It should be noted that a recent review has concluded that there is limited evidence to suggest benefit of marijuana on Tourette Syndrome17.
There have been a few limited clinical trials of THC or THC-containing products in TS. One small double-blind, placebo-controlled crossover trial of 5-10mg per day of THC in 12 adults with TS demonstrated a significant reduction in self-reported measures of tic severity and global improvement with THC compared to placebo21. A 6-week, double-blind, placebo-controlled trial of 24 adults with TS also demonstrated a significant benefit of THC compared to placebo in some, but not all, of the outcomes assessed30. Seven subjects randomly assigned to THC who completed the study experienced significant reduction of their tic symptoms compared to placebo after the first 2 weeks of treatments that continued throughout the 6-week trial. These improvements did not persist when subjects discontinued THC.
While pure CBD has been approved for the treatment of certain forms of epilepsy, epilepsy is a neuromotor disorder with a different etiology than Tourette Syndrome. There are no case reports or scientific publications indicating the effectiveness of CBD alone or medical marijuana with high percentage of CBD and low percentage of THC in TS patients, although it has been suggested that adding CBD to THC may improve efficacy27. CBD itself can also cause adverse effects and CBD products sourced on-line may not have accurate labelling and in some cases may actually contain THC even if not labeled as such31.
It is important to note that the chemicals in marijuana, like any other chemical, medicine or drug may have adverse effects. The fact that marijuana is a natural product does not necessarily make it safe. Of specific concern is the potential risk of structurally and functionally altering brain development in children and adolescents37–42. Marijuana may affect the central nervous system (cognition, vision etc.) as well as other parts of the body. Depending on the medical conditions and genetic background of a person, the use of THC-containing products can lead to psychoactive effects including psychosis, euphoria and sometimes anxious reactions. Adverse effects of cannabis depend on the content and ratio of cannabinoids and other compounds in the cannabis, route of administration, drug-drug interactions, and patient-specific factors. The most common adverse effects of THC containing products are dizziness, sedation, “high” feeling, headache, red eyes, and increased appetite13,32,33. Epidemiological evidence and pre-clinical research in healthy subjects suggest that there may be an increased risk for psychosis in children and adolescents, and depression and cognitive impairment in children and adolescents33–36. Further, there is the potential risk of structurally and functionally altering the brain development of children/adolescents with cannabis treatment or exposure to THC37–42. Lastly, cannabis may interact or adversely affect the efficacy of other prescription medications an individual is taking. CBD has been shown to inhibit the degradation of drugs by the liver43,44. As such, it increases the potency of other medications. To guard against negative drug interactions, it is important that the physician knows all other medications the patient is taking before prescribing medical marijuana.
Research will be key to better understanding what future role medical marijuana can play in the treatment plan for individuals with TS.
A call for more research
The neurobiological pathways targeted by medical marijuana and cannabis-based medicines may turn out to be promising for understanding and alleviating tic symptoms and therefore deserve more research. A recent review of literature on cannabis and cannabinoid noted that “multiple barriers to conducting research on cannabis in the U.S. may explain the paucity of positive therapeutic benefits in the published literature to date.”17
Well-designed trials are ongoing internationally (ClinicalTrials.gov Identifier: NCT03087201,
NCT03247244, NCT03066193, NCT03058562, and Australian New Zealand Clinical Trials Identifier: ACTRN12618000545268) and the Tourette Association of America is supporting research on this topic (http://www.tourette.org/ grant-database/), but more research, especially on the potential adverse effects or risks for those with TS, needs to be done.
Given the potential impact of cannabis on the developing brain, evaluating the effects of medical cannabis products in adults with TS prior to conducting similar studies in youth is recommended. In addition to studying effects on tics, clinical studies investigating the effects on cognitive function, motor control, motivation, anxiety, depression, psychosis and the impact of routine use of cannabis on functional capacity including driving, school and work performance, and interpersonal relationships need to be performed in Tourette patients.
In order to make stronger recommendations for Tourette Syndrome regarding treatment with medical cannabis and cannabis-based medicines, a series of questions need to be addressed:
- 1. Are medical cannabis and cannabis-based medicines indeed effective at reduction of tics in TS patients?
- 2. If there is an effect on tic severity, is it a direct effect on tics or a secondary effect mediated by the reduction of anxiety or other co-occurring symptoms?
- 3. If so, which specific compounds (including ratio of THC:CBD) and route of administration are most effective and best tolerated?
- 4. If so, can medical cannabis or cannabis-based medicines be used as short or long-term treatment without loss of efficacy/tolerance?
- 5. What are the specific characteristics of TS patients who are most likely to respond?
- 6. Is there a risk of medical cannabis on the developing brain, and what is the short and long-term side effect profile in pediatric and adult patients? What is the functional impact on overall motor control, mood, anxiety, driving, school and work performance, and interpersonal relationships?
Further, randomized, large-scale, placebo-controlled human studies are needed to determine the efficacy and potential risks of cannabis and cannabis-based medicines, especially over time.
Cannabis-based medicines which are FDA or EU approved for non-TS indications, meaning these are available for use under a prescription from a physician:
|Name||Content||Status and Indication/Use|
|Marinol® (Dronabinol)||A synthetic production of botanic cannabinoid THC||FDA approved for nausea and vomiting caused by cancer medicines, when other medicines did not work. Also used to increase appetite in patients with AIDS|
|Cesamet® (Nabilone)||A synthetic analogue of THC that is 4 times more potent than THC||FDA approved for nausea and vomiting that may occur during treatment with cancer medicines|
|Sativex® (nabiximols, USA)||Drug grade extract of THC:CBD in a 1:1 ratio as well as specific minor cannabinoids and other non-cannabinoid components from the cannabis Sativa plant - formulated into an oromucosal spray||Approved in the EU and Canada for spasticity related to multiple sclerosis, neuropathic pain and cancer-related pain|
|Epidiolex®||Epidiolex is a CBD extract that contains about 98% CBD and a small amount other cannabinoids including THC||FDA approved for treatment-resistant epilepsy syndromes and childhood-onset epilepsy, i.e. Lennox-Gastaut syndrome and Dravet syndrome|
Cannabis-based medicines in development for TS:
|Name||Content||Status and Indication/Use|
|THX-TS01 (or THX 110) – Therapix Biosciences||A combination of THC with palmitoylethanolamide (PEA)||Phase IIa for TS completed, showing a statistically significant reduction in tics (for details visit: http://therapix.investorroom. com/2018-04-09-Therapix-Biosciences- Announces-Topline-Results-of-Phase-IIa- Study-at-Yale-University-for-Tourette- Syndrome-Program, Phase III trial recruiting: https://clinicaltrials. gov/ct2/show/NCT03066193|
|ABX-1431 – Abide Therapeutics||A synthetic monoacylglycerol lipase (MAGL) inhibitor - stimulates the endocannabinoids system by increasing the level of 2-AG, a major endocannabinoid lipid in the brain||Phase I trial for TS completed. ABX-1431 showed a statistically significant reduction of tics and premonitory urges (for details see: http://abidetx.com/news/abide-therapeutics-reports-positive-topline-data-from-phase-1b-study-of-abx-1431-in-tourette-syndrome/), A Phase II clinical trial is now recruiting. https://clinicaltrials.gov/ct2/show/NCT03625453|
1. Batalla a, Crippa J a, Busatto GF, et al. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Curr Pharm Des. 2014. doi:10.2174/13816128113199990432
2. Beale C, Broyd SJ, Chye Y, et al. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis Cannabinoid Res. 2018. doi:10.1089/can.2017.0047
3. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry. 2018. doi:10.1176/appi.ajp.2017.17030325
4. Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014. doi:10.1038/nrn3811
5. Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular Pharmacology of Phytocannabinoids. Prog Chem Org Nat Prod. 2017. doi:10.1007/978-3-319-45541-9_3
6. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: A unified critical inventory. Nat Prod Rep. 2016. doi:10.1039/c6np00074f
7. Thomas BF, ElSohly MA. The Analytical Chemistry of Cannabis.; 2016. doi:10.1016/B978-0-12-804646-3.00003-5
8. Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis – The Canadian perspective. J Pain Res. 2016. doi:10.2147/JPR. S98182
9. Rychert M, Wilkins C, Parker K, Witten K. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand. Drug Alcohol Rev. 2018. doi:10.1111/dar.12655
10. Salani DA, Zdanowicz MM. Synthetic cannabinoids: the dangers of spicing it up. J Psychosoc Nurs Ment Health Serv. 2015. doi:10.3928/02793695-20150422-01
11. Davis C, Boddington D. Teenage Cardiac Arrest Following Abuse of Synthetic Cannabis. Hear Lung Circ. 2015. doi:10.1016/j. hlc.2015.04.176
12. Karila L, Benyamina A, Blecha L, Cottencin O, Billieux J. The Synthetic Cannabinoids Phenomenon. Curr Pharm Des. 2017. doi:10.2174/1381612822666160919093450
13. Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016. doi:10.3389/ fphar.2016.00309
14. Anavi-Goffer S, Mulder J. The polarised life of the endocannabinoid system in CNS development. ChemBioChem. 2009. doi:10.1002/cbic.200800827
15. Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016. doi:10.1016/j.biopsych.2015.07.028
16. Pertwee RG, Howlett a C, Abood ME, et al. International Union of Basic and Clinical Pharmacology . LXXIX . Cannabinoid Receptors and Their Ligands : Beyond CB 1 and CB 2. Pharmacol Rev. 2010. doi:10.1124/pr.110.003004.588
17. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018. doi:10.1016/j.ejim.2018.01.003
18. Sandyk R, Awerbuch G. Marijuana and tourette’s syndrome. J Clin Psychopharmacol. 1988. doi:10.1097/00004714- 198812000-00021
19. Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol. 1993. doi:10.1177/026988119300700411
20. Muller-Vahl K, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol .
Am J Psychiatry. 1999.
21. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002. doi:10.1055/s-2002-25028
22. Brunnauer A, Segmiller FM, Volkamer T, Laux G, Müller N, Dehning S. Cannabinoids improve driving ability in a Tourette’s patient. Psychiatry Res. 2011. doi:10.1016/j.psychres.2011.05.033
23. Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol. 2010. doi:10.1097/JCP.0b013e3181d236ec
24. Kanaan AS, Jakubovski E, Müller-Vahl K. Significant tic reduction in an otherwise treatment-resistant patient with gilles de la tourette syndrome following treatment with nabiximols. Brain Sci. 2017. doi:10.3390/brainsci7050047
25. Trainor D, Evans L, Bird R. Severe motor and vocal tics controlled with Sativex®. Australas Psychiatry. 2016. doi:10.1177/1039856216663737
26. Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette Syndrome: Cannabis-based medicines improve severe vocal blocking tics in two patients. Int J Mol Sci. 2017. doi:10.3390/ijms18081739
27. Pichler E-M, Kawohl W, Seifritz E, Roser P. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report. Int J Psychiatry Med. 2018. doi:10.1177/0091217418791455
28. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 1998. doi:10.1111/j.1600-0447.1998.tb10127.x
29. Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P. Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome. J Neuropsychiatry Clin Neurosci. 2017. doi:10.1176/appi.neuropsych.16110310
30. Müller-Vahl KR, Schneider U, Prevedel H, et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics inTourette syndrome: A 6-week randomized trial. J Clin Psychiatry. 2003. doi:10.4088/JCP.v64n0417
31. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA – J Am Med Assoc. 2017. doi:10.1001/jama.2017.11909
32. Trigo JM, Soliman A, Quilty LC, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One. 2018. doi:10.1371/journal. pone.0190768
33. Drewe M, Drewe J, Riecher-Rössler A. Cannabis and risk of psychosis. Swiss Med Wkly. 2004. doi:2004/45/smw-10802
34. Grant C, Belanger, Richard. E. Cannabis and Canada’s children and youth | Position statements and practice points | Cannabis and Canada’s children and youth | Canadian Paediatric Society. Canadian Pediatric Society.
35. Barthelemy OJ, Richardson MA, Cabral HJ, Frank DA. Prenatal, perinatal, and adolescent exposure to marijuana: Relationships with aggressive behavior. Neurotoxicol Teratol. 2016. doi:10.1016/j.ntt.2016.06.009
36. Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk of schizophrenia. J Clin Psychiatry. 2012. doi:http://dx.doi.org/10.4088/JCP.12012co1c
37. Blest-Hopley G, Giampietro V, Bhattacharyya S. Residual effects of cannabis use in adolescent and adult brains — A meta-analysis of fMRI studies. Neurosci Biobehav Rev. 2018. doi:10.1016/j.neubiorev.2018.03.008
38. Leishman E, Murphy M, Mackie K, Bradshaw HB. Δ9-Tetrahydrocannabinol changes the brain lipidome and
transcriptome differentially in the adolescent and the adult. Biochim Biophys Acta – Mol Cell Biol Lipids. 2018. doi:10.1016/j. bbalip.2018.02.001
39. Prini P, Penna F, Sciuccati E, Alberio T, Rubino T. Chronic Δ9-THC exposure differently affects histone modifications in the adolescent and adult rat brain. Int J Mol Sci. 2017. doi:10.3390/ijms18102094
40. Renard J, Rosen LG, Loureiro M, et al. Adolescent Cannabinoid Exposure Induces a Persistent Sub-Cortical Hyper-Dopami- nergic State and Associated Molecular Adaptations in the Prefrontal Cortex. Cereb Cortex. 2017. doi:10.1093/cercor/bhv335
41. Renard J, Szkudlarek HJ, Kramar CP, et al. Adolescent THC Exposure Causes Enduring Prefrontal Cortical Disruption of GABAergic Inhibition and Dysregulation of Sub-Cortical Dopamine Function /631/378/2571 /631/378/1689/1799 /9 /9/30
/82 /82/1 article. Sci Rep. 2017. doi:10.1038/s41598-017-11645-8
42. Zamberletti E, Gabaglio M, Grilli M, et al. Long-term hippocampal glutamate synapse and astrocyte dysfunctions underlying the altered phenotype induced by adolescent THC treatment in male rats. Pharmacol Res. 2016. doi:10.1016/j. phrs.2016.07.008
43. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011. doi:10.1124/dmd.111.041384
44. Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison in the In Vitro Inhibitory Effects of
Major Phytocannabinoids and Polycyclic Aromatic Hydrocarbons Contained in Marijuana Smoke on Cytochrome P450 2C9 Activity. Drug Metab Pharmacokinet. 2012. doi:10.2133/dmpk.DMPK-11-RG-107
45. Tourette Association of America. Impact Survey. 2018 TAA Impact Survey Findings. 2019. Available at: http://tourette.org/research-medical/impact-survey/. Accessed July 2, 2019.
Sharon Anavi-Goffer, PhD (University of Aberdeen) – United Kingdom
Michael Bloch, MD (Yale University) – United States
Cathy Budman, MD (Long Island Center for Tourette & Related Disorders) – United States
Barbara Coffey, MD MS (University of Miami) – United States
Keith Coffman, MD (Children’s Mercy Kansas City) – United States
Joohi Jimenez-Shahed, MD (Baylor College of Medicine) – United States
Irene Malaty, MD (University of Florida Center for Movement Disorders and Neurorestoration) – United States
Kirsten Muller-Vahl, MD (Hannover Medical School) – Germany
Paul Sandor, MD (University Health Network and University of Toronto, Toronto) – Canada
Diana Shineman, PhD (Tourette Association of America) – United States
John Walkup, MD (Lurie Children’s, Chicago) – United States
Abraham Weizman, MD (Director of Research Unit, Geha Mental Health Center) – Israel
TAA partners with many corporations including pharmaceutical companies. Abide Pharmaceuticals, mentioned in this report, is developing a synthetic monoacylglycerol lipase (MAGL) inhibitor for Tourette Syndrome, is a corporate sponsor of TAA. The TAA does not endorse any medicines or products.